¨
S. Lober, P. Gmeiner / Tetrahedron 60 (2004) 8699–8702
8702
1
(2 mL) was added. Stirring at ambient temperature for 6 h
was followed by filtration of the solvent, whereas the resin
was washed with DMF (2 mL) and CH2Cl2 (3£5 mL). The
combined filtrates were washed with a saturated solution of
NaHCO3 and evaporated to dryness to give 32 mg (68%) of
Methyl (4-(4-bromophenyl)-piperazin-1-yl)-acetate (8). H
NMR (CDCl3, 360 MHz): d (ppm)¼2.73 (t, 4H), 3.21 (t,
4H), 3.29 (s, 2H), 3.74 (s, 3H), 6.76–6.81 (m, 2H), 7.31–
7.36 (m, 2H); ESI-MS (m/z) 313, 315 (Mþ1þ).
1
7a as a colorless solid. H NMR (CDCl3, 360 MHz): d
(ppm)¼2.18 (s, 3H), 3.62 (s, 2H), 3.84 (s, 2H), 7.13 (t, 1H),
Acknowledgements
7.21–7.36 (m, 7H); ESI-MS (m/z) 276 (Mþ1þ).
The BMBF and the Fonds der Chemischen Industrie
is acknowledged for financial support. We thank
¨
Mrs R. Hofner-Stich and Mrs M. Hertel for skillful technical
assistance during the experimental work.
3.1.4. Parallel synthesis of tertiary amines (7b–f) and (8).
Tertiary amines 7b–f and 8 were synthesized following the
procedure described for 7a starting in each case from
100 mg of 5. Yields are given in Table 1. Compounds were
characterized by LCMS analysis using Agilent Zorbax
Eclipseq XDB-C8 (5 mm) and MeOH/0.1 N aq. formic acid
gradient system (50:50 to 95/5) in combination with ES
ionization and ion trap detection in positive mode and by 1H
NMR as follows.
References and notes
1. For review see: Brown, A. R.; Hermkens, P. H. H.;
Ottenheijm, H. C. J.; Rees, D. C. Synlett 1998, 817.
Balkenhohl, F.; von dem Busche-Huennefeld, C.; Lansky, A.
Angew. Chem. Int. Ed. Engl. 1996, 35, 2288.
N-Allyl-1,2,3,4-tetrahydroisochinoline (7b). 1H NMR
(CDCl3, 360 MHz): d (ppm)¼2.75 (t, 2H), 2.91 (t, 2H),
3.18 (d, 2H), 3.63 (s, 2H), 5.19 (d, 1H), 5.26 (d, 1H), 5.90–
6.01 (m, 1H), 6.99–7.13 (m, 4H); ESI-MS (m/z) 203
(Mþ1þ).
2. For review see: James, I. W. Tetrahedron 1999, 55, 4855.
¨
3. Lober, S.; Rodriguez-Loaiza, P.; Gmeiner, P. Org. Lett. 2003,
5, 1753.
4. Kolb, H. C.; Sharpless, K. B. Drug Discov. Today 2003, 8,
1128.
2-(4-Nitrobenzyl)-1,2,3,4-tetrahydroisochinoline (7c). 1H
NMR (CDCl3, 360 MHz): d (ppm)¼2.77 (t, 2H), 2.92 (t,
2H), 3.65 (s, 2H), 3.78 (s, 2H), 6.96–7.15 (m, 4H), 7.56–
7.61 (m, 2H), 8.17–8.21 (m, 2H); ESI-MS (m/z) 269
(Mþ1þ).
5. Wang, Q.; Chan, T. R.; Hilgraf, R.; Fokin, V. V.; Sharpless,
K. B.; Finn, M. G. J. Am. Chem. Soc. 2003, 125, 3192.
6. Morphy, J. R.; Rankovic, Z.; Rees, D. C. Tetrahedron Lett.
1997, 38, 3209.
7. Brown, A. R.; Rees, D. C.; Rankovic, Z.; Morphy, J. R. J. Am.
Chem. Soc. 1997, 119, 3288.
Methyl-(1,2,3,4-tetrahydroisochinolin-2-yl)-acetate (7d).
1H NMR (CDCl3, 360 MHz): d (ppm)¼2.87–2.97 (m,
4H), 3.43 (s, 2H), 3.75 (s, 3H), 3.80 (s, 2H), 6.98–7.14 (m,
4H); ESI-MS (m/z) 206 (Mþ1þ).
1-Allyl-4-phenylpiperazine (7e). 1H NMR (CDCl3,
360 MHz): d (ppm)¼2.59–2.63 (m, 4H), 3.06, (d, 2H),
3.19–3.23 (m, 4H), 5.15–5.26 (m, 2H), 5.84–5.96 (m, 1H),
6.82–6.94 (m, 3H), 7.22–7.28 (m, 2H); ESI-MS (m/z) 203
(Mþ1þ).
8. Kroll, F. E. K.; Morphy, J. R.; Rees, D.; Gani, D. Tetrahedron
Lett. 1997, 38, 8573.
9. Cottney, J.; Rankovic, Z.; Morphy, J. R. Bioorg. Med. Chem.
Lett. 1999, 9, 1323.
10. Hamper, B. C.; Kolodziej, S. A.; Scates, A. M.; Smith, R. G.;
Cortez, E. J. Org. Chem. 1998, 63, 708.
11. Bom, A.; Booth, S.; Briun, J.; Clark, J.; Miller, S.; Wathey, B.
Bioorg. Med. Chem. Lett. 2001, 11, 2351.
12. Barn, D.; Caulfield, W.; Cowley, P.; Dickens, R.; Bakker,
W. I.; McGuire, R.; Morphy, J. R.; Rankovic, Z.; Thorn, M.
J. Comb. Chem. 2001, 3, 534.
1-(4-Nitrobenzyl)-4-phenylpiperazine (7f). 1H NMR
(CDCl3, 360 MHz): d (ppm)¼2.60–2.65 (m, 4H), 3.19–
3.24 (m, 4H), 3.66 (s, 2H), 6.84–6.95 (m, 3H), 7.24–7.29
(m, 2H), 7.53–7.57 (m, 2H), 8.17–8.22 (m, 2H); ESI-MS
(m/z) 298 (Mþ1þ).
13. Arseniyadis, S.; Wagner, A.; Mioskowski, C. Tetrahedron
Lett. 2002, 43, 9717.
14. Propargyl acrylate was purchased from Sigma-Aldrich.
15. Koskinen, A. M. P.; Rapoport, H. J. Org. Chem. 1989, 54,
1859.